公开(公告)号：US20220218850A1

公开(公告)日：2022-07-14

申请号：US17574790

申请日：2022-01-13

Applicant: Virginia Commonwealth University

Inventor： Paul B. Fisher ,  Luni Emdad ,  Praveen Bhoopathi ,  Anjan K. Pradhan ,  Swadesh K. Das ,  Alexander L. Klibanov

IPC: A61K49/22 ,  A61K45/06 ,  A61K31/7115

Abstract: In various aspects, the present disclosure provides methods, compositions, and kits for treating a target tissue with one or more active agents. In embodiments, delivering an active agent to a target tissue comprises administration of microbubbles and ultrasound.

公开(公告)号：US20210147502A1

公开(公告)日：2021-05-20

申请号：US17082523

申请日：2020-10-28

Applicant: Virginia Commonwealth University

Inventor： Paul B. Fisher ,  Praveen Bhoopathi ,  Swadesh K. Das ,  Luni Emdad ,  Devanand Sarkar ,  Upneet Sokhi

IPC: C07K14/54

Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

公开(公告)号：US20240360138A1

公开(公告)日：2024-10-31

申请号：US18537700

申请日：2023-12-12

Applicant: Virginia Commonwealth University ,  Sanford Burnham Prebys Medical Discovery Institute

Inventor： Paul B. Fisher ,  Maurizio Pellecchia ,  Swadesh K. Das ,  Timothy P. Kegelman ,  Bainan Wu ,  Surya K. De ,  Jun Wei ,  Mitchell E. Menezes ,  Luni Emdad

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  C07D495/14

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  C07D495/14

Abstract: Provided herein are, inter alia, compositions that bind to a PDZI domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

公开(公告)号：US11891399B2

公开(公告)日：2024-02-06

申请号：US17148813

申请日：2021-01-14

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY ,  SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

Inventor： Paul B. Fisher ,  Maurizio Pellecchia ,  Swadesh K. Das ,  Timothy P. Kegelman ,  Bainan Wu ,  Surya K. De ,  Jun Wei ,  Mitchell E. Menezes ,  Luni Emdad

IPC: C07D487/04 ,  C07D495/14 ,  A61P35/04 ,  A61K45/06 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  C07D495/14 ,  A61K31/519 ,  A61K2300/00

Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

公开(公告)号：US11008325B2

公开(公告)日：2021-05-18

申请号：US16349467

申请日：2017-11-14

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY ,  SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

Inventor： Paul B. Fisher ,  Maurizio Pellecchia ,  Swadesh K. Das ,  Timothy P. Kegelman ,  Bainan Wu ,  Surya K. De ,  Jun Wei ,  Mitchell E. Menezes ,  Luni Emdad

IPC: C07D487/04 ,  C07D495/14 ,  A61P35/04 ,  A61K31/519 ,  A61K45/06

Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

公开(公告)号：US20180305429A1

公开(公告)日：2018-10-25

申请号：US15956409

申请日：2018-04-18

Applicant: Virginia Commonwealth University

Inventor： Paul B. Fisher ,  Praveen Bhoopathi ,  Swadesh K. Das ,  Luni Emdad ,  Devanand Sarkar ,  Upneet Sokhi

IPC: C07K14/54 ,  A61K38/00

CPC classification number: C07K14/5428 ,  A61K38/00 ,  C07K14/54 ,  C07K2319/055

Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

公开(公告)号：US09951114B2

公开(公告)日：2018-04-24

申请号：US14895138

申请日：2014-06-04

Applicant: Virginia Commonwealth University

Inventor： Paul B. Fisher ,  Praveen Bhoopathi ,  Swadesh K. Das ,  Luni Emdad ,  Devanand Sarkar ,  Upneet Sokhi

IPC: A61K38/00 ,  C07K14/00 ,  C07K14/54

CPC classification number: C07K14/5428 ,  A61K38/00 ,  C07K14/54 ,  C07K2319/055

Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

公开(公告)号：US20160108101A1

公开(公告)日：2016-04-21

申请号：US14895138

申请日：2014-06-04

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Paul B. Fisher ,  Praveen Bhoopathi ,  Swadesh K. Das ,  Luni Emdad ,  Devanand Sarkar ,  Upneet Sokhi

IPC: C07K14/54

CPC classification number: C07K14/5428 ,  A61K38/00 ,  C07K14/54 ,  C07K2319/055

Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

Abstract translation: 提供了用于治疗癌症的重组治疗细胞因子（“治疗”）。 重组酶包括自然界中通常没有发现具有抗癌活性的MDA-7 / TL-24（“M4”）的截短区域，以及导致质粒/病毒转导的正常和癌细胞分泌的热分解信号 以及相邻的，相邻的和远处的癌细胞上的热激蛋白与MDA-7 / IL-24受体的相互作用。 治疗相互作用导致旁观者杀死靶癌细胞以及相邻，相邻和远处的癌细胞。